Compare Banco Bilbao Vizcaya Argentaria SA (BBVA) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Bilbao Vizcaya Argentaria SA vs Medtronic PLC — how do they compare? Banco Bilbao Vizcaya Argentaria SA trades at $28.62 (market cap $157.51B), while Medtronic PLC trades at $90.79 (market cap $114.45B). The key difference: Banco Bilbao Vizcaya Argentaria SA is the larger of the two by market cap, and Banco Bilbao Vizcaya Argentaria SA pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| BBVA | MDT | |
|---|---|---|
Market Cap | $157.51B | $114.45B |
Sector | Financials | Health |
52-Week High | $28.36 | $105.35 |
52-Week Low | $17.96 | $73.75 |
Dividend Yield | 3.8% | 3.22% |
Enterprise Value | — | $133.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBVA trades at $28.35, up 0.75% today, with a bullish technical signal from moving averages and strong fundamental performance. The bank reported Q2 2026 net profit growth of 11.4% year-over-year, driven by Mexico operations, and announced a $2.3 billion buyback. Revenue reached $39.42 billion in 2025, with net income margin at 26.13% and ROE of 18.5%, though cash flow was negative in 2024.
Outlook is positive with raised profitability guidance (ROTE ~21%) and analyst consensus leaning buy (54%), but risks include a Spanish court trial for spying allegations and antitrust probes. The stock offers value with a P/E of 12.98, yet investors should monitor legal overhangs and macroeconomic volatility in core markets like Spain and Mexico.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
